| Year |
Citation |
Score |
| 2024 |
Tenshin H, Delgado-Calle J, Windle JJ, Roodman GD, Chirgwin JM, Kurihara N. Osteocytes and Paget's Disease of Bone. Current Osteoporosis Reports. PMID 38457001 DOI: 10.1007/s11914-024-00863-5 |
0.339 |
|
| 2023 |
Marino S, Petrusca DN, Bishop RT, Anderson JL, Sabol HM, Ashby C, Layer JH, Cesarano A, Davé UP, Perna F, Delgado-Calle J, Chirgwin JM, Roodman GD. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma. Haematologica. PMID 37981834 DOI: 10.3324/haematol.2023.283787 |
0.411 |
|
| 2023 |
Okui T, Hiasa M, Hata K, Roodman GD, Nakanishi M, Yoneda T. The acid-sensing nociceptor TRPV1 controls breast cancer progression in bone via regulating HGF secretion from sensory neurons. Research Square. PMID 37461623 DOI: 10.21203/rs.3.rs-3105966/v1 |
0.36 |
|
| 2023 |
Delgado-Calle J, Roodman GD. Doubling Down on Wnt Signaling to Overcome Myeloma Bone Disease. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 38: 812-813. PMID 37277117 DOI: 10.1002/jbmr.4863 |
0.326 |
|
| 2022 |
Sabol HM, Amorim T, Ashby C, Halladay D, Anderson J, Cregor M, Sweet M, Nookaew I, Kurihara N, Roodman GD, Bellido T, Delgado-Calle J. Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. Neoplasia (New York, N.Y.). 28: 100785. PMID 35390742 DOI: 10.1016/j.neo.2022.100785 |
0.318 |
|
| 2022 |
Delgado-Calle J, McAndrews K, Wu G, Orr AL, Ferrari A, Tu X, Srinivasan V, Roodman GD, Ebetino FH, Boeckman RK, Bellido T. The Notch pathway regulates the bone gain induced by PTH anabolic signaling. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 36: e22196. PMID 35137455 DOI: 10.1096/fj.202101807R |
0.377 |
|
| 2021 |
Sabol HM, Ferrari AJ, Adhikari M, Amorim T, McAndrews K, Anderson J, Vigolo M, Lehal R, Cregor M, Khan S, Cuevas PL, Helms JA, Kurihara N, Srinivasan V, Ebetino FH, ... ... Roodman GD, et al. Targeting Notch inhibitors to the myeloma bone marrow niche decreases tumor growth and bone destruction without gut toxicity. Cancer Research. PMID 34348968 DOI: 10.1158/0008-5472.CAN-21-0524 |
0.42 |
|
| 2021 |
Okui T, Hiasa M, Ryumon S, Ono K, Kunisada Y, Ibaragi S, Sasaki A, Roodman GD, White FA, Yoneda T. The HMGB1/RAGE axis induces bone pain associated with colonization of 4T1 mouse breast cancer in bone. Journal of Bone Oncology. 26: 100330. PMID 33204606 DOI: 10.1016/j.jbo.2020.100330 |
0.35 |
|
| 2020 |
Mulcrone PL, Edwards SKE, Petrusca DN, Haneline LS, Delgado-Calle J, Roodman GD. Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23. Scientific Reports. 10: 17319. PMID 33057033 DOI: 10.1038/s41598-020-74352-x |
0.348 |
|
| 2020 |
Whyte MP, Campeau PM, McAlister WH, Roodman GD, Kurihara N, Nenninger A, Duan S, Gottesman GS, Bijanki VN, Sedighi H, Veis DJ, Mumm S. Juvenile Paget's Disease From Heterozygous Mutation of SP7 Encoding Osterix (Specificity Protein 7, Transcription Factor SP7). Bone. 137: 115364. PMID 32298837 DOI: 10.1016/J.Bone.2020.115364 |
0.405 |
|
| 2020 |
Miyagawa K, Ohata Y, Delgado-Calle J, Teramachi J, Zhou H, Dempster DW, Subler MA, Windle JJ, Chirgwin J, Roodman GD, Kurihara N. Osteoclast-derived IGF1 is required for pagetic lesion formation in vivo. Jci Insight. PMID 32078587 DOI: 10.1172/Jci.Insight.133113 |
0.385 |
|
| 2019 |
Marino S, Petrusca DN, Roodman GD. Therapeutic targets in myeloma bone disease. British Journal of Pharmacology. PMID 31647573 DOI: 10.1111/Bph.14889 |
0.51 |
|
| 2019 |
Delgado-Calle J, Kurihara N, Atkinson EG, Nelson J, Miyagawa K, Galmarini CM, Roodman GD, Bellido T. Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts. Oncotarget. 10: 2709-2721. PMID 31105871 DOI: 10.18632/Oncotarget.26831 |
0.529 |
|
| 2019 |
Adamik J, Roodman GD, Galson DL. Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease. Jbmr Plus. 3: e10183. PMID 30918921 DOI: 10.1002/jbm4.10183 |
0.428 |
|
| 2019 |
Marino S, Petrusca DN, Simpson E, Anderson JL, Xie X, Liu Y, Chirgwin J, Roodman GD. Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors Blood. 134: 4391-4391. DOI: 10.1182/Blood-2019-131865 |
0.507 |
|
| 2019 |
Teramachi J, Miyagawa K, Jesus D, Windle J, Kurihara N, Roodman GD. Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM Blood. 134: 4336-4336. DOI: 10.1182/Blood-2019-126959 |
0.399 |
|
| 2019 |
Rangaraju S, Marino S, Roodman GD, Cripe LD, Ramdas B, Palam LR, Sargent KJ, Sayar H, Konig H, Kapur R, Boswell HS. Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations Blood. 134: 5051-5051. DOI: 10.1182/Blood-2019-124384 |
0.311 |
|
| 2019 |
Ferrari AJ, McAndrews K, Nelson JH, Bell JT, Srinivasan V, Ebetino FH, Boeckman RK, Roodman GD, Bellido T, Delgado-Calle J. Abstract 103: Disruption of Notch Signaling targeted to the myeloma bone marrow microenvironment simultaneously inhibits tumor growth and prevents bone loss without inducing gut toxicity Cancer Research. 79: 103-103. DOI: 10.1158/1538-7445.Am2019-103 |
0.518 |
|
| 2018 |
Adamik J, Galson DL, Roodman GD. Osteoblast suppression in multiple myeloma bone disease. Journal of Bone Oncology. 13: 62-70. PMID 30591859 DOI: 10.1016/J.Jbo.2018.09.001 |
0.511 |
|
| 2018 |
Petrusca DN, Toscani D, Wang FM, Park C, Crean CD, Anderson JL, Marino S, Mohammad KS, Zhou D, Silbermann R, Sun Q, Kurihara N, Galson DL, Giuliani N, Roodman GD. Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis. Journal of Hematology & Oncology. 11: 123. PMID 30286780 DOI: 10.1186/S13045-018-0666-5 |
0.462 |
|
| 2018 |
Adamik J, Silbermann R, Marino S, Sun Q, Anderson JL, Zhou D, Xie XQ, Roodman GD, Galson DL. XRK3F2 Inhibition of p62-ZZ Domain Signaling Rescues Myeloma-Induced GFI1-Driven Epigenetic Repression of the Gene in Pre-osteoblasts to Overcome Differentiation Suppression. Frontiers in Endocrinology. 9: 344. PMID 30008697 DOI: 10.3389/Fendo.2018.00344 |
0.444 |
|
| 2018 |
Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, Legieć W, Krejčí M, Laribi K, Zhu L, Cheng P, Warner D, Roodman GD. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. The Lancet. Oncology. PMID 29429912 DOI: 10.1016/S1470-2045(18)30072-X |
0.411 |
|
| 2018 |
Anderson K, Ismaila N, Flynn PJ, Halabi S, Jagannath S, Ogaily MS, Omel J, Raje N, Roodman GD, Yee GC, Kyle RA. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017766402. PMID 29341831 DOI: 10.1200/Jco.2017.76.6402 |
0.383 |
|
| 2018 |
Marino S, Roodman GD. Multiple Myeloma and Bone: The Fatal Interaction. Cold Spring Harbor Perspectives in Medicine. 8. PMID 29229668 DOI: 10.1101/Cshperspect.A031286 |
0.506 |
|
| 2018 |
Sun Q, Zhang P, Adamik J, Lontos K, Marchica V, Giuliani N, Silbermann RW, Roodman GD, Galson DL. TBK1/Ikkε Inhibitor Amlx Blocks Multiple Myeloma Cell Growth in Vitro and In Vivo Blood. 132: 4504-4504. DOI: 10.1182/Blood-2018-99-119677 |
0.341 |
|
| 2018 |
Suvannasankha A, Crean C, Ochoa IC, Roodman GD, Chirgwin J. PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease Blood. 132: 4450-4450. DOI: 10.1182/Blood-2018-99-115680 |
0.519 |
|
| 2018 |
Rangaraju S, Marino S, Petrusca DN, Cripe LD, Sargent KJ, Roodman GD, Sayar H, Ramdas B, Palam LR, Shanmugam R, Rogozea A, Konig H, Kapur R, Boswell HS. Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML Blood. 132: 3949-3949. DOI: 10.1182/Blood-2018-99-111181 |
0.316 |
|
| 2017 |
Delgado-Calle J, Anderson J, Cregor MD, Condon KW, Kuhstoss SA, Plotkin LI, Bellido T, Roodman GD. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia. 31: 2686-2694. PMID 28529307 DOI: 10.1038/leu.2017.152 |
0.431 |
|
| 2017 |
Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. Journal of Bone Oncology. 7: 1-12. PMID 28413771 DOI: 10.1016/J.Jbo.2017.03.001 |
0.356 |
|
| 2017 |
Hiasa M, Okui T, Allette YM, Ripsch MS, Sun-Wada GH, Wakabayashi H, Roodman GD, White FA, Yoneda T. Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3. Cancer Research. PMID 28254863 DOI: 10.1158/0008-5472.Can-15-3545 |
0.442 |
|
| 2017 |
Adamik J, Jin S, Sun Q, Zhang P, Weiss KR, Anderson JL, Silbermann R, Roodman GD, Galson DL. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation. Molecular Cancer Research : McR. PMID 28119431 DOI: 10.1158/1541-7786.Mcr-16-0242-T |
0.375 |
|
| 2017 |
Raje NS, Roodman GD, Willenbacher W, Shimizu K, Garcia-Sanz R, Durie BG, Zhu L, Cheng PC, Bhatta S, Terpos E. Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease. Journal of Clinical Oncology. 35: 8005-8005. DOI: 10.1200/Jco.2017.35.15_Suppl.8005 |
0.308 |
|
| 2017 |
Suvannasankha A, Abonour R, Farag S, Silbermann RW, Wongsaengsak S, Cangany MH, Rush-Taylor A, Tann M, Althouse SK, Perkins SM, Roodman GD. Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma Blood. 130: 1826-1826. DOI: 10.1182/Blood.V130.Suppl_1.1826.1826 |
0.453 |
|
| 2017 |
Raje N, Terpos E, Willenbacher W, Shimizu K, Garcia-Sanz R, Durie B, Legiec W, Krejci M, Laribi K, Zhu L, Cheng P, Warner D, Roodman GD. An International, Randomized, Double Blind Trial Comparing Denosumab With Zoledronic Acid (ZA) for the Treatment of Bone Disease in Patients (Pts) With Newly Diagnosed Multiple Myeloma Clinical Lymphoma Myeloma and Leukemia. 17: e27-e28. DOI: 10.1016/J.Clml.2017.03.047 |
0.39 |
|
| 2016 |
Fu J, Li S, Feng R, Ma H, Sabeh F, Roodman GD, Wang J, Robinson S, Guo XE, Lund T, Normolle D, Mapara MY, Weiss SJ, Lentzsch S. Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. The Journal of Clinical Investigation. PMID 27043283 DOI: 10.1172/Jci80276 |
0.456 |
|
| 2016 |
Silbermann R, Roodman GD. Current Controversies in the Management of Myeloma Bone Disease. Journal of Cellular Physiology. PMID 26910829 DOI: 10.1002/jcp.25351 |
0.322 |
|
| 2016 |
Teramachi J, Nagata Y, Mohammad K, Inagaki Y, Ohata Y, Guise T, Michou L, Brown JP, Windle JJ, Kurihara N, Roodman GD. Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease. The Journal of Clinical Investigation. PMID 26878170 DOI: 10.1172/Jci82012 |
0.442 |
|
| 2016 |
Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, Yoneda T, Mohammad KS, Plotkin LI, Roodman GD, Bellido T. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma. Cancer Research. 76: 1089-100. PMID 26833121 DOI: 10.1158/0008-5472.CAN-15-1703 |
0.465 |
|
| 2016 |
Silbermann R, Adamik J, Zhou D, Xie X, Kurihara N, Galson DL, Roodman GD. p62-ZZ domain signaling inhibition prevents MM cell-induced epigenetic repression at the Runx2 promoter and rescues osteoblast differentiation Bone Abstracts. DOI: 10.1530/Boneabs.5.Cabs.Op1.4 |
0.351 |
|
| 2016 |
Suvannasankha A, Crean CD, Tompkins DR, Delgado-Calle J, Bellido TM, Roodman GD, Chirgwin JM. Regulation of Osteoblast Function in Myeloma Bone Disease By Semaphorin 4D Blood. 128: 4439-4439. DOI: 10.1182/Blood.V128.22.4439.4439 |
0.54 |
|
| 2016 |
Toscani D, Park C, Wang F, Anderson J, Giuliani N, Roodman GD, Petrusca DN. Gfi1 Transcription Factor Is a Pro-Survival Molecule in Multiple Myeloma Cells Blood. 128: 4422-4422. DOI: 10.1182/Blood.V128.22.4422.4422 |
0.422 |
|
| 2016 |
Ohata Y, Chirgwin JM, Windle JJ, Roodman GD, Kurihara N. Myeloma Cells Induce High Level of TAF12 Expression in Bone Marrow Stromal Cells, Resulting in Increased Osteoclastogenesis and Myeloma Cell Growth in Response to 1,25(OH)2D3 Blood. 128: 4421-4421. DOI: 10.1182/Blood.V128.22.4421.4421 |
0.45 |
|
| 2016 |
Silbermann R, Adamik J, Zhou D, Xie X, Kurihara N, Roodman GD, Galson DL. p62-ZZ Domain Signaling Inhibition Rescues MM-Induced Epigenetic Repression at the Runx2 promoter and Allows Osteoblast Differentiation of MM Patient Pre-Osteoblasts In Vitro Blood. 128: 4410-4410. DOI: 10.1182/Blood.V128.22.4410.4410 |
0.497 |
|
| 2016 |
Adamik J, Silbermann R, Lontos K, Zhang P, Sun Q, Galson DL, Roodman GD. EZH2 Inhibitor GSK126 Exhibits Osteo-Anabolic Properties in MM Bone Disease and Synergizes with Bortezomib to Inhibit MM Cell Viability Blood. 128: 3247-3247. DOI: 10.1182/Blood.V128.22.3247.3247 |
0.524 |
|
| 2016 |
Delgado-Calle J, Anderson J, Cregor MD, Zhou D, Plotkin LI, Bellido TM, Roodman GD. Genetic Sost Deletion and Pharmacological Inhibition of Sclerostin Prevent Multiple Myeloma-Induced Bone Loss without Affecting Tumor Growth Blood. 128: 1136-1136. DOI: 10.1182/Blood.V128.22.1136.1136 |
0.462 |
|
| 2015 |
Roodman GD, Silbermann R. Mechanisms of osteolytic and osteoblastic skeletal lesions Bonekey Reports. 4: 753-753. PMID 26539296 DOI: 10.1038/Bonekey.2015.122 |
0.462 |
|
| 2015 |
Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, Chiechi A, Wright LE, Umanskaya A, Niewolna M, Trivedi T, Charkhzarrin S, Khatiwada P, Wronska A, Haynes A, ... ... Roodman GD, et al. Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nature Medicine. PMID 26457758 DOI: 10.1038/Nm.3961 |
0.368 |
|
| 2015 |
Teramachi J, Silbermann R, Yang P, Zhao W, Mohammad KS, Guo J, Anderson JL, Zhou D, Feng R, Myint KZ, Maertz N, Beumer JH, Eiseman JL, Windle JJ, Xie XQ, ... Roodman GD, et al. Blocking the ZZ domain of sequestosome 1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo. Leukemia. PMID 26286116 DOI: 10.1038/leu.2015.229 |
0.431 |
|
| 2015 |
Feng R, Tong Q, Xie Z, Cheng H, Wang L, Lentzsch S, Roodman GD, Xie XQ. Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption. Molecular Carcinogenesis. PMID 25640641 DOI: 10.1002/Mc.22251 |
0.376 |
|
| 2015 |
Adamik J, Ding J, Zhao W, Zhang P, Sun Q, Roodman GD, Galson DL. LIM-Domain Protein Ajuba Is a Required Co-Factor for Gfi1-Induced Epigenetic Switch Regulating Runx2 Repression in Multiple Myeloma-Exposed Pre-Osteoblasts Blood. 126: 4216-4216. DOI: 10.1182/Blood.V126.23.4216.4216 |
0.44 |
|
| 2015 |
Fu J, Li S, Roodman GD, Mapara M, Weiss SJ, Lentzsch S. Mechanism Study of Matrix Metalloproteinase 13 Effects on Osteoclast Activation and Lytic Bone Lesions in Multiple Myeloma Blood. 126: 3009-3009. DOI: 10.1182/Blood.V126.23.3009.3009 |
0.401 |
|
| 2015 |
Delgado-Calle J, Anderson J, Cregor MD, Carlesso N, Mohammad KS, Plotkin LI, Bellido TM, Roodman GD. Bidirectional Notch Signaling Between Multiple Myeloma (MM) Cells and Osteocytes As a Potential Target to Inhibit Tumor Growth and Osteoclast Recruitment in MM Blood. 126: 2977-2977. DOI: 10.1182/Blood.V126.23.2977.2977 |
0.52 |
|
| 2015 |
Silbermann R, Adamik J, Zhou D, Xie X, Roodman GD, Kurihara N, Galson DL. p62-ZZ Domain Inhibition Prevents MM Cell-Induced Epigenetic Changes at the Runx2 and C/EBPb Promoters Blood. 126: 1796-1796. DOI: 10.1182/Blood.V126.23.1796.1796 |
0.467 |
|
| 2014 |
Delgado-Calle J, Bellido T, Roodman GD. Role of osteocytes in multiple myeloma bone disease. Current Opinion in Supportive and Palliative Care. 8: 407-13. PMID 25289928 DOI: 10.1097/Spc.0000000000000090 |
0.505 |
|
| 2014 |
Bon J, Kahloon R, Zhang Y, Xue J, Fuhrman CR, Tan J, Burger M, Kass DJ, Csizmadia E, Otterbein L, Chandra D, Bhargava A, Pilewski JM, Roodman GD, Sciurba FC, et al. Autoreactivity to glucose regulated protein 78 links emphysema and osteoporosis in smokers. Plos One. 9: e105066. PMID 25216103 DOI: 10.1371/Journal.Pone.0105066 |
0.338 |
|
| 2014 |
Galson DL, Roodman GD. Pathobiology of Paget's Disease of Bone. Journal of Bone Metabolism. 21: 85-98. PMID 25025000 DOI: 10.11005/Jbm.2014.21.2.85 |
0.46 |
|
| 2014 |
Raje NS, Yee AJ, Roodman GD. Advances in supportive care for multiple myeloma. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 502-11. PMID 24717569 DOI: 10.6004/Jnccn.2014.0055 |
0.314 |
|
| 2014 |
Terpos E, Berenson J, Raje N, Roodman GD. Management of bone disease in multiple myeloma. Expert Review of Hematology. 7: 113-25. PMID 24433088 DOI: 10.1586/17474086.2013.874943 |
0.446 |
|
| 2014 |
Teramachi J, Zhou H, Subler MA, Kitagawa Y, Galson DL, Dempster DW, Windle JJ, Kurihara N, Roodman GD. Increased IL-6 expression in osteoclasts is necessary but not sufficient for the development of Paget's disease of bone. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 29: 1456-65. PMID 24339057 DOI: 10.1002/Jbmr.2158 |
0.392 |
|
| 2014 |
Sun Q, Sammut B, Wang FM, Kurihara N, Windle JJ, Roodman GD, Galson DL. TBK1 mediates critical effects of measles virus nucleocapsid protein (MVNP) on pagetic osteoclast formation. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 29: 90-102. PMID 23794264 DOI: 10.1002/Jbmr.2026 |
0.485 |
|
| 2014 |
Yoneda TN, Hiasa MN, Nagata YN, Ripsch MS, White FA, Roodman GD. Acidic Extracellular Microenvironment in Myeloma-Colonized Bone Contributes to Bone Pain Blood. 124: 3397-3397. DOI: 10.1182/Blood.V124.21.3397.3397 |
0.457 |
|
| 2014 |
Storti P, Donofrio G, Marchica V, Guasco D, Todoerti K, Airoldi I, Anderson J, Bolzoni M, Ferri V, Martella E, Mancini C, Campanini N, Neri A, Roodman GD, Aversa F, et al. Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma Blood. 124: 3373-3373. DOI: 10.1182/Blood.V124.21.3373.3373 |
0.454 |
|
| 2014 |
Delgado-Calle J, Anderson J, Plotkin LI, Bellido T, Roodman GD. Notch- and TNFα-Activated Signaling Pathways Mediate Osteocyte Apoptosis Triggered By Multiple Myeloma Cells Blood. 124: 3354-3354. DOI: 10.1182/Blood.V124.21.3354.3354 |
0.444 |
|
| 2014 |
Silbermann R, Zhou D, Teramachi J, Xie X, Roodman GD, Kurihara N. The p62-ZZ Domain Inhibitor XRK3F2 Alters Myeloma-Induced Suppression of Osteoblast Differentiation and Is Highly Cytotoxic to Myeloma Cells in Combination with Bortezomib Blood. 124: 2083-2083. DOI: 10.1182/Blood.V124.21.2083.2083 |
0.534 |
|
| 2014 |
Kurihara N, Kitagawa Y, Inagaki Y, Windle JJ, Chirgwin JM, Roodman GD. TAF12 Enhances the Biological Reponses of Myeloma Cells to Low Concentrations of 1,25-(OH)2dvitamin D3 Blood. 124: 2066-2066. DOI: 10.1182/Blood.V124.21.2066.2066 |
0.446 |
|
| 2013 |
Silbermann R, Roodman GD. Myeloma bone disease: Pathophysiology and management. Journal of Bone Oncology. 2: 59-69. PMID 26909272 DOI: 10.1016/J.Jbo.2013.04.001 |
0.53 |
|
| 2013 |
Cao H, Zhu K, Qiu L, Li S, Niu H, Hao M, Yang S, Zhao Z, Lai Y, Anderson JL, Fan J, Im HJ, Chen D, Roodman GD, Xiao G. Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis. The Journal of Biological Chemistry. 288: 30399-410. PMID 24005670 DOI: 10.1074/Jbc.M113.469973 |
0.519 |
|
| 2013 |
Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, García-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, ... ... Roodman GD, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2347-57. PMID 23690408 DOI: 10.1200/Jco.2012.47.7901 |
0.31 |
|
| 2013 |
Teramachi J, Hiruma Y, Ishizuka S, Ishizuka H, Brown JP, Michou L, Cao H, Galson DL, Subler MA, Zhou H, Dempster DW, Windle JJ, Roodman GD, Kurihara N. Role of ATF7-TAF12 interactions in the vitamin D response hypersensitivity of osteoclast precursors in Paget's disease. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 28: 1489-500. PMID 23426901 DOI: 10.1002/Jbmr.1884 |
0.365 |
|
| 2013 |
Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C, Agnelli L, Patrene K, Maïga S, Franceschi V, Colla S, Anderson J, ... ... Roodman GD, et al. Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia. 27: 1697-706. PMID 23344526 DOI: 10.1038/Leu.2013.24 |
0.408 |
|
| 2013 |
Wang FM, Sarmasik A, Hiruma Y, Sun Q, Sammut B, Windle JJ, Roodman GD, Galson DL. Measles virus nucleocapsid protein, a key contributor to Paget's disease, increases IL-6 expression via down-regulation of FoxO3/Sirt1 signaling. Bone. 53: 269-76. PMID 23262029 DOI: 10.1016/J.Bone.2012.12.007 |
0.456 |
|
| 2013 |
Fu J, Li S, Ma H, Roodman GD, Mapara MY, Weiss SJ, Lentzsch S. Knockdown Of Matrix Metalloproteinase 13 (MMP13) In 5TGM1 Multiple Myeloma Cells Inhibits Development Of Lytic Bone Lesions In Vivo Blood. 122: 879-879. DOI: 10.1182/Blood.V122.21.879.879 |
0.449 |
|
| 2013 |
Wang F, Adamik J, Rushdan S, Jin S, Ding J, Galson DL, Roodman GD. Increase of Gfi1 Acetylation by HDAC Inhibitors Blocks Gfi1-Mediated Runx2 Repression in Osteoblast Precursors in Multiple Myeloma Bone Disease Blood. 122: 753-753. DOI: 10.1182/Blood.V122.21.753.753 |
0.429 |
|
| 2013 |
Silbermann R, Zhao W, Eiseman JL, Beumer JH, Xie X, Yang P, Myint K, Wang L, Feng Z, Windle JJ, Roodman GD, Kurihara N. A Novel Sequestosome-1/p62 ZZ Domain Inhibitor Induces New Bone Formation In The Presence Of Myeloma In Vivo Blood. 122: 684-684. DOI: 10.1182/Blood.V122.21.684.684 |
0.467 |
|
| 2013 |
Bolzoni M, Storti P, Guasco D, Anderson J, Windle JJ, Roodman GD, Giuliani N. IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A Blood. 122: 3101-3101. DOI: 10.1182/Blood.V122.21.3101.3101 |
0.427 |
|
| 2013 |
Ding J, Wang F, Jin S, Anderson J, Galson DL, Roodman GD. The Transcription Repressor Gfi1 Directly Interacts With and Is Phosphorylated By Aurora A Kinase, Which Abrogates Myeloma-Induced Gfi1 Repression Of The Runx2 Promoter In Pre-Osteoblasts Blood. 122: 1184-1184. DOI: 10.1182/Blood.V122.21.1844.1844 |
0.463 |
|
| 2013 |
Bilezikian JP, Bouillon R, Clemens T, Compston J, Bauer DC, Ebeling PR, Engelke K, Goltzman D, Guise T, Beur SMJD, Jüppner H, Lyons K, McCauley L, McClung MR, Miller PD, ... ... Roodman GD, et al. Primer on the metabolic bone diseases and disorders of mineral metabolism. Journal of Bone and Joint Surgery-British Volume. 1087-1087. DOI: 10.1002/9781119266594 |
0.357 |
|
| 2012 |
Galson DL, Silbermann R, Roodman GD. Mechanisms of multiple myeloma bone disease. Bonekey Reports. 1: 135. PMID 23951515 DOI: 10.1038/Bonekey.2012.135 |
0.518 |
|
| 2012 |
Roodman GD. Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Reviews. 31: 569-78. PMID 22706844 DOI: 10.1007/S10555-012-9372-X |
0.501 |
|
| 2012 |
Roodman GD. Vitamin E: good for the heart, bad for the bones? Nature Medicine. 18: 491-2. PMID 22481404 DOI: 10.1038/Nm.2718 |
0.419 |
|
| 2012 |
Xu G, Liu K, Anderson J, Patrene K, Lentzsch S, Roodman GD, Ouyang H. Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood. 119: 4205-14. PMID 22427205 DOI: 10.1182/Blood-2011-05-353300 |
0.529 |
|
| 2012 |
D'Souza S, Kurihara N, Shiozawa Y, Joseph J, Taichman R, Galson DL, Roodman GD. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood. 119: 1888-96. PMID 22223826 DOI: 10.1182/Blood-2011-11-393348 |
0.44 |
|
| 2012 |
Roodman GD. Mechanisms of bone metastasis. Discovery Medicine. 4: 144-8. PMID 20704976 |
0.36 |
|
| 2012 |
Fu J, Li S, Feng R, Ma H, Sabeh F, Roodman GD, Mapara M, Weiss SJ, Lentzsch S. Matrix Metalloproteinase 13 (MMP13) Upregulation Is Essential for Multiple Myeloma Related Bone Lytic Lesion Blood. 120: 4025-4025. DOI: 10.1182/Blood.V120.21.4025.4025 |
0.455 |
|
| 2012 |
Teramachi J, Kurihara N, Chirgwin JM, Roodman GD. The Increased 1,25-(OH)2D3 Sensitivity of Myeloma Cells and Marrow Stromal Cells Enhances RANKL Production and Tumor Cell Growth Blood. 120: 3946-3946. DOI: 10.1182/Blood.V120.21.3946.3946 |
0.427 |
|
| 2012 |
Bolzoni M, Storti P, Donofrio G, Airoldi I, Guasco D, Toscani D, Peronaci M, Martella E, Lazzaretti M, Agnelli L, Patrene K, Mancini C, Amiot M, Neri A, Colla S, ... ... Roodman GD, et al. Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo. Blood. 120: 2947-2947. DOI: 10.1182/Blood.V120.21.2947.2947 |
0.398 |
|
| 2011 |
D'Souza S, del Prete D, Jin S, Sun Q, Huston AJ, Kostov FE, Sammut B, Hong CS, Anderson JL, Patrene KD, Yu S, Velu CS, Xiao G, Grimes HL, Roodman GD, et al. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood. 118: 6871-80. PMID 22042697 DOI: 10.1182/Blood-2011-04-346775 |
0.546 |
|
| 2011 |
Silbermann R, Roodman GD. Bone effects of cancer therapies: pros and cons. Current Opinion in Supportive and Palliative Care. 5: 251-7. PMID 21768880 DOI: 10.1097/Spc.0B013E328349C524 |
0.456 |
|
| 2011 |
Wang FM, Galson DL, Roodman GD, Ouyang H. Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells. Experimental Hematology. 39: 999-1006. PMID 21723843 DOI: 10.1016/J.Exphem.2011.06.007 |
0.302 |
|
| 2011 |
Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1278-86. PMID 21411443 DOI: 10.1158/1078-0432.Ccr-10-1804 |
0.506 |
|
| 2011 |
Kurihara N, Hiruma Y, Yamana K, Michou L, Rousseau C, Morissette J, Galson DL, Teramachi J, Zhou H, Dempster DW, Windle JJ, Brown JP, Roodman GD. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metabolism. 13: 23-34. PMID 21195346 DOI: 10.1016/J.Cmet.2010.12.002 |
0.388 |
|
| 2011 |
Jung Y, Shiozawa Y, Wang J, Patel LR, Havens AM, Song J, Krebsbach PH, Roodman GD, Taichman RS. Annexin-2 is a regulator of stromal cell-derived factor-1/CXCL12 function in the hematopoietic stem cell endosteal niche. Experimental Hematology. 39: 151-166.e1. PMID 21108988 DOI: 10.1016/J.Exphem.2010.11.007 |
0.353 |
|
| 2011 |
Ishizuka H, García-Palacios V, Lu G, Subler MA, Zhang H, Boykin CS, Choi SJ, Zhao L, Patrene K, Galson DL, Blair HC, Hadi TM, Windle JJ, Kurihara N, Roodman GD. ADAM8 enhances osteoclast precursor fusion and osteoclast formation in vitro and in vivo. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 26: 169-81. PMID 20683884 DOI: 10.1002/Jbmr.199 |
0.488 |
|
| 2011 |
Roodman GD. Osteoblast function in myeloma. Bone. 48: 135-40. PMID 20601285 DOI: 10.1016/J.Bone.2010.06.016 |
0.539 |
|
| 2011 |
Silbermann R, Bolzoni M, Storti P, Palma BD, Bonomini S, Anderson J, Roodman GD, Giuliani N. Bone Marrow Monocyte / Macrophage Derived Activin A Mediates the Osteoclastogenic Effects of IL-3 in Myeloma, Blood. 118: 3933-3933. DOI: 10.1182/Blood.V118.21.3933.3933 |
0.492 |
|
| 2010 |
Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, Callander N, Katodritou E, Tussing-Humphreys L, Rivera S, Vanderkerken K, Lichtenstein A, Ganz T. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood. 116: 3635-44. PMID 20679527 DOI: 10.1182/Blood-2010-03-274571 |
0.444 |
|
| 2010 |
Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood. 116: 3554-63. PMID 20664052 DOI: 10.1182/Blood-2010-05-283895 |
0.526 |
|
| 2010 |
Cao H, Yu S, Yao Z, Galson DL, Jiang Y, Zhang X, Fan J, Lu B, Guan Y, Luo M, Lai Y, Zhu Y, Kurihara N, Patrene K, Roodman GD, et al. Activating transcription factor 4 regulates osteoclast differentiation in mice. The Journal of Clinical Investigation. 120: 2755-66. PMID 20628199 DOI: 10.1172/Jci42106 |
0.488 |
|
| 2010 |
Dossa T, Arabian A, Windle JJ, Dedhar S, Teitelbaum SL, Ross FP, Roodman GD, St-Arnaud R. Osteoclast-specific inactivation of the integrin-linked kinase (ILK) inhibits bone resorption. Journal of Cellular Biochemistry. 110: 960-7. PMID 20564195 DOI: 10.1002/Jcb.22609 |
0.432 |
|
| 2010 |
Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. British Journal of Haematology. 150: 28-38. PMID 20507313 DOI: 10.1111/J.1365-2141.2010.08207.X |
0.301 |
|
| 2010 |
Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: advancing treatment and prevention. Cancer Treatment Reviews. 36: 615-20. PMID 20478658 DOI: 10.1016/J.Ctrv.2010.04.003 |
0.461 |
|
| 2010 |
Roodman GD. Insights into the pathogenesis of Paget's disease. Annals of the New York Academy of Sciences. 1192: 176-80. PMID 20392234 DOI: 10.1111/J.1749-6632.2009.05214.X |
0.374 |
|
| 2010 |
Roodman GD. Targeting the bone microenvironment in multiple myeloma. Journal of Bone and Mineral Metabolism. 28: 244-50. PMID 20127498 DOI: 10.1007/S00774-009-0154-7 |
0.506 |
|
| 2010 |
Roodman GD. Pathogenesis of myeloma bone disease. Journal of Cellular Biochemistry. 109: 283-91. PMID 20014067 DOI: 10.1002/jcb.22403 |
0.409 |
|
| 2010 |
Pal R, Monaghan SA, Hassett AC, Mapara MY, Schafer P, Roodman GD, Ragni MV, Moscinski L, List A, Lentzsch S. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood. 115: 605-14. PMID 19965623 DOI: 10.1182/Blood-2009-05-221077 |
0.309 |
|
| 2010 |
Cackowski FC, Anderson JL, Patrene KD, Choksi RJ, Shapiro SD, Windle JJ, Blair HC, Roodman GD. Osteoclasts are important for bone angiogenesis. Blood. 115: 140-9. PMID 19887675 DOI: 10.1182/Blood-2009-08-237628 |
0.722 |
|
| 2010 |
Li S, Feng R, Ma H, Roodman GD, Mapara MY, Lentzsch S. Lenalidomide Upregulates CXCR4 on CD34+ Hematopoietic Cells Resulting In Increased Binding to Bone Marrow Niche and Inhibiting Mobilization Into Peripheral Blood In Multiple Myeloma Patients Blood. 116: 4079-4079. DOI: 10.1182/Blood.V116.21.4079.4079 |
0.393 |
|
| 2009 |
Levy J, Roodman GD. The role of bisphosphonates in multiple myeloma. Current Hematologic Malignancy Reports. 4: 108-12. PMID 20425422 DOI: 10.1007/S11899-009-0015-4 |
0.483 |
|
| 2009 |
Lipton A, Uzzo R, Amato RJ, Ellis GK, Hakimian B, Roodman GD, Smith MR. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. Journal of the National Comprehensive Cancer Network : Jnccn. 7: S1-29; quiz S30. PMID 19878635 DOI: 10.6004/Jnccn.2009.0080 |
0.481 |
|
| 2009 |
Yu S, Franceschi RT, Luo M, Fan J, Jiang D, Cao H, Kwon TG, Lai Y, Zhang J, Patrene K, Hankenson K, Roodman GD, Xiao G. Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone. Plos One. 4: e7583. PMID 19851510 DOI: 10.1371/Journal.Pone.0007583 |
0.469 |
|
| 2009 |
Pal R, Janz M, Galson DL, Gries M, Li S, Jöhrens K, Anagnostopoulos I, Dörken B, Mapara MY, Borghesi L, Kardava L, Roodman GD, Milcarek C, Lentzsch S. C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells. Blood. 114: 3890-8. PMID 19717648 DOI: 10.1182/Blood-2009-01-201111 |
0.332 |
|
| 2009 |
Roodman GD. Osteoclasts pump iron. Cell Metabolism. 9: 405-6. PMID 19416710 DOI: 10.1016/J.Cmet.2009.04.005 |
0.406 |
|
| 2009 |
Hiruma Y, Honjo T, Jelinek DF, Windle JJ, Shin J, Roodman GD, Kurihara N. Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood. 113: 4894-902. PMID 19282458 DOI: 10.1182/Blood-2008-08-173948 |
0.454 |
|
| 2009 |
Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 23: 435-41. PMID 19039321 DOI: 10.1038/leu.2008.336 |
0.405 |
|
| 2009 |
Choi SJ, Roodman GD, Feng JQ, Song IS, Amin K, Hart PS, Wright JT, Haruyama N, Hart TC. In vivo impact of a 4 bp deletion mutation in the DLX3 gene on bone development. Developmental Biology. 325: 129-37. PMID 18996110 DOI: 10.1016/j.ydbio.2008.10.014 |
0.385 |
|
| 2009 |
D'Souza S, Prete DD, Esteve F, Sammut B, Yu S, Xiao G, Galson D, Roodman GD. Multiple Myeloma Cell Induction of GFI-1 in Stromal Cells Suppresses Osteoblast Differentiation in Patients with Myeloma. Blood. 114: 742-742. DOI: 10.1182/Blood.V114.22.742.742 |
0.487 |
|
| 2009 |
Feng R, Huang X, Coulton L, Raeve HD, DiLiberto M, Ely S, Xiao G, Luo M, Menu E, Croucher P, Roodman GD, Vanderkerken K, Chen-Kiang S, Lentzsch S. Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma. Blood. 114: 298-298. DOI: 10.1182/Blood.V114.22.298.298 |
0.404 |
|
| 2009 |
Feng R, Ma H, Kurihara N, Li S, Ziegler JA, Mapara MY, Roodman GD, Lentzsch S. Nocodazole Induces Multiple Myeloma Cell Death and Reduces Tumor Growth through Sequential Microtubular Network Damage and C-Jun N-Terminal Kinase-Mediated Bcl-2 Phosphorylation. Blood. 114: 296-296. DOI: 10.1182/Blood.V114.22.296.296 |
0.418 |
|
| 2009 |
Feng R, Kurihara N, Ma H, Roodman GD, Lentzsch S. Matrix Metalloproteinses-13 (Collagenase-3) Secreted by Multiple Myeloma Cells Enhances the Bone Resorptive Activity of Osteoclasts. Blood. 114: 2853-2853. DOI: 10.1182/Blood.V114.22.2853.2853 |
0.463 |
|
| 2009 |
Siris ES, Roodman GD. Chapter 72. Paget's Disease of Bone Primer On the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 335-343. DOI: 10.1002/9780470623992.Ch72 |
0.443 |
|
| 2008 |
Timmons MM, Garbern J, Robey PG, Singleton A, Hernandez DG, Roodman GD, Zaltz I, Mumm S, Wilcox W, Fischbeck KH, Brady RO, Knight MA. WITHDRAWN: Familial Degenerative Encephalopathy with Intracranial Calcification and Metaphyseal Dysplasia. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. PMID 19016590 DOI: 10.1359/Jbmr.081110 |
0.363 |
|
| 2008 |
Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6387-95. PMID 18927277 DOI: 10.1158/1078-0432.Ccr-08-1572 |
0.476 |
|
| 2008 |
Roodman GD. Novel targets for myeloma bone disease. Expert Opinion On Therapeutic Targets. 12: 1377-87. PMID 18851694 DOI: 10.1517/14728222.12.11.1377 |
0.523 |
|
| 2008 |
Hiruma Y, Kurihara N, Subler MA, Zhou H, Boykin CS, Zhang H, Ishizuka S, Dempster DW, Roodman GD, Windle JJ. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Human Molecular Genetics. 17: 3708-19. PMID 18765443 DOI: 10.1093/Hmg/Ddn266 |
0.439 |
|
| 2008 |
Ishizuka S, Kurihara N, Hiruma Y, Miura D, Namekawa J, Tamura A, Kato-Nakamura Y, Nakano Y, Takenouchi K, Hashimoto Y, Nagasawa K, Roodman GD. 1alpha,25-Dihydroxyvitamin D(3)-26,23-lactam analogues function as vitamin D receptor antagonists in human and rodent cells. The Journal of Steroid Biochemistry and Molecular Biology. 110: 269-77. PMID 18501591 DOI: 10.1016/J.Jsbmb.2007.11.007 |
0.308 |
|
| 2008 |
Roodman GD. Bone building with bortezomib. The Journal of Clinical Investigation. 118: 462-4. PMID 18219395 DOI: 10.1172/Jci34734 |
0.517 |
|
| 2008 |
Roodman GD, Dougall WC. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treatment Reviews. 34: 92-101. PMID 17964729 DOI: 10.1016/J.Ctrv.2007.09.002 |
0.508 |
|
| 2008 |
Pal R, Roodman GD, Mapara M, Mocsinski L, List AF, Lentzsch S. Immunomodulatory Derivatives of Thalidomide (IMiD)-Induced Neutropenia Is Associated with PU.1 Downregulation and Myeloid Maturation Arrest Blood. 112: 845-845. DOI: 10.1182/Blood.V112.11.845.845 |
0.448 |
|
| 2008 |
Feng R, Huang X, Roodman GD, Chen-Kiang S, Lentzsch S. Inhibition of Cdk4/6 by PD 0332991 Results in Abrogation of Osteoclast Formation Blood. 112: 3676-3676. DOI: 10.1182/Blood.V112.11.3676.3676 |
0.38 |
|
| 2008 |
Roodman GD. Mechanisms of bone metastasis, pathophysiology of osteonecrosis of the jaw, and integrins, platelets and bone metastasis: meeting report from skeletal complications of malignancy V Ibms Bonekey. 5: 294-296. DOI: 10.1138/20080332 |
0.343 |
|
| 2008 |
Roodman GD. PL1.3. Developments in bone target treatment of cancer Cancer Treatment Reviews. 34: 1. DOI: 10.1016/J.Ctrv.2008.03.014 |
0.403 |
|
| 2007 |
Esteve FR, Roodman GD. Pathophysiology of myeloma bone disease. Best Practice & Research. Clinical Haematology. 20: 613-24. PMID 18070709 DOI: 10.1016/J.Beha.2007.08.003 |
0.51 |
|
| 2007 |
Cackowski FC, Roodman GD. Perspective on the osteoclast: an angiogenic cell? Annals of the New York Academy of Sciences. 1117: 12-25. PMID 18056034 DOI: 10.1196/Annals.1402.073 |
0.717 |
|
| 2007 |
Lentzsch S, Ehrlich LA, Roodman GD. Pathophysiology of multiple myeloma bone disease. Hematology/Oncology Clinics of North America. 21: 1035-49, viii. PMID 17996587 DOI: 10.1016/J.Hoc.2007.08.009 |
0.794 |
|
| 2007 |
Lentzsch S, Elliott G, Roodman GD. SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma. Archiv Der Pharmazie. 340: 511-6. PMID 17849446 DOI: 10.1002/Ardp.200700081 |
0.318 |
|
| 2007 |
Roodman GD. Treatment strategies for bone disease. Bone Marrow Transplantation. 40: 1139-46. PMID 17680018 DOI: 10.1038/sj.bmt.1705802 |
0.444 |
|
| 2007 |
Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Research. 67: 3646-53. PMID 17440076 DOI: 10.1158/0008-5472.Can-06-1210 |
0.472 |
|
| 2007 |
Roodman GD. Bone-breaking cancer treatment. Nature Medicine. 13: 25-6. PMID 17206127 DOI: 10.1038/Nm0107-25 |
0.414 |
|
| 2007 |
Kurihara N, Hiruma Y, Zhou H, Subler MA, Dempster DW, Singer FR, Reddy SV, Gruber HE, Windle JJ, Roodman GD. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. The Journal of Clinical Investigation. 117: 133-42. PMID 17187080 DOI: 10.1172/Jci28267 |
0.389 |
|
| 2007 |
Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Côté D, Veilleux I, ... ... Roodman GD, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 109: 2708-17. PMID 17119115 DOI: 10.1182/Blood-2006-07-035857 |
0.398 |
|
| 2007 |
Feng R, Anderson G, Xiao G, Elliott G, Leoni L, Mapara MY, Roodman GD, Lentzsch S. SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood. 109: 2130-8. PMID 17095620 DOI: 10.1182/Blood-2006-07-027458 |
0.497 |
|
| 2007 |
Garcia-Palacios V, Chung HY, Choi SJ, Sarmasik A, Kurihara N, Lee JW, Galson DL, Collins R, Roodman GD. Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing in osteoclast precursors expression of LFA-1 and ICAM-1. Bone. 40: 316-22. PMID 16996813 DOI: 10.1016/J.Bone.2006.08.004 |
0.38 |
|
| 2007 |
Pal R, Kennedy R, Mansour LR, Stirling D, Mapara MY, Roodman GD, Lentzsch S. Cathepsin G, a Potent Platelet Aggregation Activator, Is Upregulated in Multiple Myeloma Patients during Treatment with Lenalidomide (Revlimid). Blood. 110: 2504-2504. DOI: 10.1182/Blood.V110.11.2504.2504 |
0.305 |
|
| 2006 |
Reddy GK, Mughal TI, Roodman GD. Novel approaches in the management of myeloma-related skeletal complications. Supportive Cancer Therapy. 4: 15-8. PMID 18632461 DOI: 10.3816/SCT.2006.n.026 |
0.366 |
|
| 2006 |
Kurihara N, Zhou H, Reddy SV, Garcia Palacios V, Subler MA, Dempster DW, Windle JJ, Roodman GD. Experimental models of Paget's disease. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 21: P55-7. PMID 17229020 DOI: 10.1359/Jbmr.06S210 |
0.421 |
|
| 2006 |
Singer FR, Mills BG, Gruber HE, Windle JJ, Roodman GD. Ultrastructure of bone cells in Paget's disease of bone. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 21: P51-4. PMID 17229009 DOI: 10.1359/Jbmr.06S209 |
0.496 |
|
| 2006 |
Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, et al. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6826-35. PMID 17121904 DOI: 10.1158/1078-0432.Ccr-06-1331 |
0.716 |
|
| 2006 |
Roodman GD. New potential targets for treating myeloma bone disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6270s-6273s. PMID 17062712 DOI: 10.1158/1078-0432.Ccr-06-0845 |
0.492 |
|
| 2006 |
Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, et al. Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6209s-6212s. PMID 17062702 DOI: 10.1158/1078-0432.Ccr-06-1213 |
0.447 |
|
| 2006 |
Rao H, Lu G, Kajiya H, Garcia-Palacios V, Kurihara N, Anderson J, Patrene K, Sheppard D, Blair HC, Windle JJ, Choi SJ, Roodman GD. Alpha9beta1: a novel osteoclast integrin that regulates osteoclast formation and function. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 21: 1657-65. PMID 16995821 DOI: 10.1359/Jbmr.060718 |
0.446 |
|
| 2006 |
Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Experimental Hematology. 34: 1289-95. PMID 16982321 DOI: 10.1016/J.Exphem.2006.06.017 |
0.47 |
|
| 2006 |
Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood. 108: 3992-6. PMID 16917004 DOI: 10.1182/blood-2006-05-026112 |
0.448 |
|
| 2006 |
Lu G, Maeda H, Reddy SV, Kurihara N, Leach R, Anderson JL, Roodman GD. Cloning and characterization of the annexin II receptor on human marrow stromal cells. The Journal of Biological Chemistry. 281: 30542-50. PMID 16895901 DOI: 10.1074/Jbc.M607072200 |
0.301 |
|
| 2006 |
Garcia-Palacios V, Chung HY, Choi SJ, Kurihara N, Lee JW, Ehrlich LA, Collins R, Roodman GD. Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing ICAM-1 expression. Annals of the New York Academy of Sciences. 1068: 240-3. PMID 16831924 DOI: 10.1196/Annals.1346.048 |
0.735 |
|
| 2006 |
Roodman GD. Regulation of osteoclast differentiation. Annals of the New York Academy of Sciences. 1068: 100-9. PMID 16831910 DOI: 10.1196/Annals.1346.013 |
0.397 |
|
| 2006 |
Huston A, Roodman GD. Role of the microenvironment in multiple myeloma bone disease. Future Oncology (London, England). 2: 371-8. PMID 16787117 DOI: 10.2217/14796694.2.3.371 |
0.518 |
|
| 2006 |
Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D, Damm D, Reddy M, Ma JY, Haghnazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, ... ... Roodman GD, et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Experimental Cell Research. 312: 1909-23. PMID 16600214 DOI: 10.1016/J.Yexcr.2006.02.026 |
0.549 |
|
| 2006 |
Kurihara N, Zhou H, Reddy SV, Garcia Palacios V, Subler MA, Dempster DW, Windle JJ, Roodman GD. Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 21: 446-55. PMID 16491293 DOI: 10.1359/Jbmr.051108 |
0.433 |
|
| 2005 |
Ehrlich LA, Roodman GD. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma. Immunological Reviews. 208: 252-66. PMID 16313353 DOI: 10.1111/J.0105-2896.2005.00323.X |
0.772 |
|
| 2005 |
Roodman GD. High bone turnover markers predict poor outcome in patients with bone metastasis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4821-2. PMID 15983398 DOI: 10.1200/Jco.2005.02.911 |
0.472 |
|
| 2005 |
Li F, Chung H, Reddy SV, Lu G, Kurihara N, Zhao AZ, Roodman GD. Annexin II stimulates RANKL expression through MAPK. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 20: 1161-7. PMID 15940368 DOI: 10.1359/Jbmr.050207 |
0.318 |
|
| 2005 |
Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S, Rizzoli V, Roodman GD, Giuliani N. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 106: 1407-14. PMID 15878977 DOI: 10.1182/Blood-2005-03-1080 |
0.768 |
|
| 2005 |
Roodman GD. Mechanisms of bone resorption in myeloma. Journal of Musculoskeletal & Neuronal Interactions. 3: 271-2; discussion 29. PMID 15758296 |
0.367 |
|
| 2005 |
Oba Y, Lee JW, Ehrlich LA, Chung HY, Jelinek DF, Callander NS, Horuk R, Choi SJ, Roodman GD. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Experimental Hematology. 33: 272-8. PMID 15730850 DOI: 10.1016/J.Exphem.2004.11.015 |
0.748 |
|
| 2005 |
Ishizuka S, Kurihara N, Reddy SV, Cornish J, Cundy T, Roodman GD. (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease. Endocrinology. 146: 2023-30. PMID 15618361 DOI: 10.1210/En.2004-1140 |
0.381 |
|
| 2005 |
Ghobrial IM, Melhem M, Singha U, George D, Timm M, Francis L, Alsayed Y, Huston A, Roodman GD, Greipp P, Gertz M, Witzig T. Role of the Chemokine Receptor CXCR4 in Waldenstrom Macroglobulinemia. Blood. 106: 993-993. DOI: 10.1182/Blood.V106.11.993.993 |
0.497 |
|
| 2005 |
Kurihara N, Honjo T, Windle JJ, Shin J, Roodman GD. Targeting p62ZIP in Marrow Stromal Cells Is Highly Effective at Inhibiting Myeloma Cell Growth and Osteoclast Formation. Blood. 106: 630-630. DOI: 10.1182/Blood.V106.11.630.630 |
0.378 |
|
| 2005 |
Alsayed Y, Timm M, Leontovich A, Santos D, Ho A, Singha U, Francis L, Huston A, Lu G, Lentzsch S, Roodman GD, Xavier L, Treon S, Ghobrial IM. Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) Using Nanoscale Protein Micorarray Techniques. Blood. 106: 504-504. DOI: 10.1182/Blood.V106.11.504.504 |
0.309 |
|
| 2005 |
Francis L, Anderson J, Timm M, Kurihara N, Singha U, Alsayed Y, Huston A, Lentzsch S, Roodman GD, Ghobrial IM. The Effect of Rapamycin, 17-AAG and the Combination on the Bone Marrow Microenvironment in Multiple Myeloma (MM). Blood. 106: 3476-3476. DOI: 10.1182/BLOOD.V106.11.3476.3476 |
0.305 |
|
| 2005 |
Huston A, Singha U, Alsayed Y, Francis L, Lu G, Anderson J, Lentzsch S, Roodman GD, Ghobrial IM. The Role of the AKT Inhibitor Perifosine in Migration and Adhesion in Multiple Myeloma (MM). Blood. 106: 2509-2509. DOI: 10.1182/Blood.V106.11.2509.2509 |
0.387 |
|
| 2005 |
Ghobrial I, Singha U, Alsayed Y, Huston A, Francis L, Lu G, Anderson J, Lentzsch S, Roodman GD. Molecular Mechanisms Regulating Migration and Adhesion in Response to the Chemokine SDF-1 in Multiple Myeloma (MM). Blood. 106: 2491-2491. DOI: 10.1182/Blood.V106.11.2491.2491 |
0.372 |
|
| 2005 |
Alsayed Y, Singha U, Francis L, Huston A, Lu G, Anderson J, Lentzsch S, Roodman GD, Ghobrial IM. Combination of the mTOR Inhibitor Rapamycin with the HSP90 Inhibitor 17-AAG Has Synergistic Activity in EBV Positive Post Transplant Lymphoproliferative Disorders (PTLD). Blood. 106: 2414-2414. DOI: 10.1182/Blood.V106.11.2414.2414 |
0.35 |
|
| 2005 |
Alsayed Y, Singha U, Francis L, Huston A, Lu G, Anderson J, Lentzsch S, Roodman GD, Ghobrial I. Differential Response to Proteosome Inhibition in EBV Positive and Negative Lymphoma Cell Lines: Clinical Implications in Post Transplant Lymphoproliferative Disorders (PTLD). Blood. 106: 2413-2413. DOI: 10.1182/Blood.V106.11.2413.2413 |
0.344 |
|
| 2005 |
Huston A, Francis L, Alsayed Y, Singha U, Lu G, Anderson J, Lentzsch S, Roodman GD, Ghobrial I. Combination of the AKT Inhibitor Perifosine with the HSP90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin (17-DMAG) Has Synergistic Activity in Multiple Myeloma (MM). Blood. 106: 1592-1592. DOI: 10.1182/Blood.V106.11.1592.1592 |
0.368 |
|
| 2005 |
Roodman GD. Book Review Textbook of Bone Metastases Edited by Claude Jasmin, Robert E. Coleman, Lawrence R. Coia, Rodolfo Capanna, and Gérard Saillant. 568 pp., illustrated. Chichester, England, John Wiley & Sons, 2005. $350. 0-471-87742-5 New England Journal of Medicine. 353: 2311-2311. DOI: 10.1056/Nejm200511243532127 |
0.365 |
|
| 2004 |
Ishizuka S, Kurihara N, Miura D, Takenouchi K, Cornish J, Cundy T, Reddy SV, Roodman GD. Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells. The Journal of Steroid Biochemistry and Molecular Biology. 89: 331-4. PMID 15225795 DOI: 10.1016/J.Jsbmb.2004.03.025 |
0.439 |
|
| 2004 |
Kurihara N, Ishizuka S, Demulder A, Menaa C, Roodman GD. Paget's disease-a VDR coactivator disease? The Journal of Steroid Biochemistry and Molecular Biology. 321-5. PMID 15225793 DOI: 10.1016/J.Jsbmb.2004.03.023 |
0.378 |
|
| 2004 |
Roodman GD. Mechanisms of bone metastasis. The New England Journal of Medicine. 350: 1655-64. PMID 15084698 DOI: 10.1056/NEJMRA030831 |
0.349 |
|
| 2004 |
Roodman GD, Choi SJ. MIP-1 alpha and myeloma bone disease. Cancer Treatment and Research. 118: 83-100. PMID 15043189 DOI: 10.1007/978-1-4419-9129-4_4 |
0.477 |
|
| 2004 |
Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells, Molecules & Diseases. 32: 290-2. PMID 15003820 DOI: 10.1016/j.bcmd.2004.01.001 |
0.432 |
|
| 2004 |
Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood. 103: 2308-15. PMID 14615378 DOI: 10.1182/Blood-2003-06-1992 |
0.765 |
|
| 2004 |
Ehrlich LA, Ito M, Choi SJ, Roodman GD. IL-3 Inhibits Osteoblast Formation in Multiple Myeloma Via CD45+ Cells. Blood. 104: 2347-2347. DOI: 10.1182/Blood.V104.11.2347.2347 |
0.754 |
|
| 2004 |
Roodman GD. Osteoclasts and myeloma cells stick together Blood. 104: 2209-2209. DOI: 10.1182/Blood-2004-07-2724 |
0.417 |
|
| 2004 |
Roodman GD. Erratum to ?Pathogenesis of myeloma bone disease? 6Blood Cells Mol. Dis. 32 (2004) 290?2929 Blood Cells Molecules and Diseases. 33: 95. DOI: 10.1016/S1079-9796(04)00096-8 |
0.474 |
|
| 2004 |
Roodman GD. Erratum: Pathogenesis of myeloma bone disease (Blood Cells, Molecules, and Diseases (2004) 32 (290-292) DOI: 10.1016/j.bcmd.2004.01.001) Blood Cells Molecules and Diseases. 33. DOI: 10.1016/J.Bcmd.2004.04.007 |
0.428 |
|
| 2003 |
Roccisana JL, Kawanabe N, Kajiya H, Koide M, Roodman GD, Reddy SV. Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells. The Journal of Biological Chemistry. 279: 10500-7. PMID 14699143 DOI: 10.1074/Jbc.M303727200 |
0.441 |
|
| 2003 |
Choi SJ, Oba T, Callander NS, Jelinek DF, Roodman GD. AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma. Blood. 101: 3778-83. PMID 12560229 DOI: 10.1182/Blood-2002-08-2641 |
0.348 |
|
| 2003 |
Anderson KC, Shaughnessy JD, Barlogie B, Harousseau JL, Roodman GD. Multiple myeloma. Hematology. American Society of Hematology. Education Program. 214-40. PMID 12446425 DOI: 10.1182/asheducation-2002.1.214 |
0.36 |
|
| 2003 |
Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 17: 1921-5. PMID 12412796 DOI: 10.1359/Jbmr.2002.17.11.1921 |
0.486 |
|
| 2002 |
Sezer O, Heider U, Jakob C, Eucker J, Possinger K, Roodman GD. Human bone marrow myeloma cells express RANKL. Journal of Clinical Oncology. 20: 353-354. PMID 11773196 DOI: 10.1200/Jco.2002.20.1.353 |
0.498 |
|
| 2002 |
Friedrichs WE, Reddy SV, Bruder JM, Cundy T, Cornish J, Singer FR, Roodman GD. Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 17: 145-51. PMID 11771661 DOI: 10.1359/Jbmr.2002.17.1.145 |
0.4 |
|
| 2002 |
Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J, Roodman GD. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. The Journal of Clinical Investigation. 108: 1833-41. PMID 11748267 DOI: 10.1172/jci13116 |
0.409 |
|
| 2002 |
Choi SJ, Kurihara N, Oba Y, Roodman GD. Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 16: 1804-11. PMID 11585344 DOI: 10.1359/Jbmr.2001.16.10.1804 |
0.419 |
|
| 2001 |
Roodman GD. Studies in Paget's disease and their relevance to oncology. Seminars in Oncology. 28: 15-21. PMID 11544571 DOI: 10.1016/S0093-7754(01)90227-1 |
0.509 |
|
| 2001 |
Callander NS, Roodman GD. Myeloma bone disease. Seminars in Hematology. 38: 276-85. PMID 11486316 DOI: 10.1016/S0037-1963(01)90020-4 |
0.533 |
|
| 2001 |
Roodman GD. Biology of osteoclast activation in cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 3562-71. PMID 11481364 DOI: 10.1200/JCO.2001.19.15.3562 |
0.451 |
|
| 2001 |
Reddy SV, Kurihara N, Menaa C, Landucci G, Forthal D, Koop BA, Windle JJ, Roodman GD. Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts. Endocrinology. 142: 2898-905. PMID 11416009 DOI: 10.1210/Endo.142.7.8255 |
0.309 |
|
| 2001 |
Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood. 97: 3349-53. PMID 11369623 DOI: 10.1182/BLOOD.V97.11.3349 |
0.304 |
|
| 2001 |
Choi SJ, Han JH, Roodman GD. ADAM8: a novel osteoclast stimulating factor. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 16: 814-22. PMID 11341326 DOI: 10.1359/Jbmr.2001.16.5.814 |
0.423 |
|
| 2001 |
Cruz JC, Alsina M, Craig F, Yoneda T, Anderson JL, Dallas M, Roodman GD. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma Experimental Hematology. 29: 441-447. PMID 11301184 DOI: 10.1016/S0301-472X(01)00618-X |
0.439 |
|
| 2001 |
Whyte MP, Mills BG, Reinus WR, Podgornik MN, Roodman GD, Gannon FH, Eddy MC, McAlister WH. Expansile skeletal hyperphosphatasia: a new familial metabolic bone disease. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 15: 2330-44. PMID 11127198 DOI: 10.1359/Jbmr.2000.15.12.2330 |
0.466 |
|
| 2000 |
Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, Alsina M. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma Blood. 96: 671-675. PMID 10887133 |
0.329 |
|
| 2000 |
Menaa C, Reddy SV, Kurihara N, Maeda H, Anderson D, Cundy T, Cornish J, Singer FR, Bruder JM, Roodman GD. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. The Journal of Clinical Investigation. 105: 1833-8. PMID 10862799 DOI: 10.1172/Jci9133 |
0.439 |
|
| 2000 |
Menaa C, Barsony J, Reddy SV, Cornish J, Cundy T, Roodman GD. 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 15: 228-36. PMID 10703924 DOI: 10.1359/Jbmr.2000.15.2.228 |
0.358 |
|
| 2000 |
Hentunen TA, Choi SJ, Boyce BF, Dallas MR, Dallas SL, Shen-Ong GL, Roodman GD. A murine model of inflammatory bone disease. Bone. 26: 183-8. PMID 10678414 DOI: 10.1016/S8756-3282(99)00247-1 |
0.408 |
|
| 2000 |
Menaa C, Kurihara N, Roodman GD. CFU-GM-derived cells form osteoclasts at a very high efficiency. Biochemical and Biophysical Research Communications. 267: 943-6. PMID 10673396 DOI: 10.1006/Bbrc.1999.2042 |
0.378 |
|
| 2000 |
Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, Alsina M. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma Blood. 96: 671-675. DOI: 10.1182/BLOOD.V96.2.671.014K24_671_675 |
0.393 |
|
| 2000 |
Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, Alsina M. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma Blood. 96: 671-675. DOI: 10.1182/blood.v96.2.671 |
0.393 |
|
| 1999 |
Hentunen TA, Jackson SH, Chung H, Reddy SV, Lorenzo J, Choi SJ, Roodman GD. Characterization of Immortalized Osteoclast Precursors Developed from Mice Transgenic for Both bcl-XL and Simian Virus 40 Large T Antigen. Endocrinology. 140: 2954-2961. PMID 28204334 DOI: 10.1210/Endo.140.7.6867 |
0.345 |
|
| 1999 |
Reddy SV, Menaa C, Singer FR, Cundy T, Cornish J, Whyte MP, Roodman GD. Measles virus nucleocapsid transcript expression is not restricted to the osteoclast lineage in patients with Paget's disease of bone. Experimental Hematology. 27: 1528-32. PMID 10517494 DOI: 10.1016/S0301-472X(99)00097-1 |
0.351 |
|
| 1999 |
Leach RJ, Singer FR, Cody JD, Roodman GD. Variable disease severity associated with a Paget's disease predisposition gene. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 17-20. PMID 10510208 DOI: 10.1002/Jbmr.5650140205 |
0.302 |
|
| 1999 |
Reddy SV, Menaa C, Singer FR, Demulder A, Roodman GD. Cell biology of Paget's disease. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 3-8. PMID 10510206 DOI: 10.1002/Jbmr.5650140203 |
0.475 |
|
| 1999 |
Choi SJ, Reddy SV, Devlin RD, Menaa C, Chung H, Boyce BF, Roodman GD. Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption. The Journal of Biological Chemistry. 274: 27747-53. PMID 10488118 DOI: 10.1074/JBC.274.39.27747 |
0.413 |
|
| 1999 |
Roodman GD. Cell biology of the osteoclast. Experimental Hematology. 27: 1229-41. PMID 10428500 DOI: 10.1016/S0301-472X(99)00061-2 |
0.417 |
|
| 1999 |
Menaa C, Devlin RD, Reddy SV, Gazitt Y, Choi SJ, Roodman GD. Annexin II increases osteoclast formation by stimulating the proliferation of osteoclast precursors in human marrow cultures. The Journal of Clinical Investigation. 103: 1605-13. PMID 10359570 DOI: 10.1172/JCI6374 |
0.334 |
|
| 1999 |
Roodman GD. Mechanisms of abnormal bone turnover in Paget's disease. Bone. 24: 39S-40S. PMID 10321925 DOI: 10.1016/S8756-3282(99)00045-9 |
0.333 |
|
| 1999 |
Reddy S, Devlin R, Menaa C, Nishimura R, Choi SJ, Dallas M, Yoneda T, Roodman GD. Isolation and characterization of a cDNA clone encoding a novel peptide (OSF) that enhances osteoclast formation and bone resorption. Journal of Cellular Physiology. 177: 636-45. PMID 10092216 DOI: 10.1002/(SICI)1097-4652(199812)177:4<636::AID-JCP14>3.0.CO;2-H |
0.399 |
|
| 1998 |
Choi SJ, Devlin RD, Menaa C, Chung H, Roodman GD, Reddy SV. Cloning and identification of human Sca as a novel inhibitor of osteoclast formation and bone resorption. The Journal of Clinical Investigation. 102: 1360-8. PMID 9769328 DOI: 10.1172/JCI2667 |
0.421 |
|
| 1998 |
Reddy SV, Roodman GD. Control of osteoclast differentiation. Critical Reviews in Eukaryotic Gene Expression. 8: 1-17. PMID 9673448 DOI: 10.1615/CRITREVEUKARGENEEXPR.V8.I1.10 |
0.4 |
|
| 1998 |
Roodman GD, Ohsaki Y, Miller MM, Demulder A, Hosking D, Singer FR, McManus LM. Pagetic osteoclasts formed in vitro: absence of paracrystalline inclusions. Journal of Submicroscopic Cytology and Pathology. 30: 315-27. PMID 9648296 |
0.377 |
|
| 1998 |
Devlin RD, Reddy SV, Savino R, Ciliberto G, Roodman GD. IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 13: 393-9. PMID 9525339 DOI: 10.1359/Jbmr.1998.13.3.393 |
0.401 |
|
| 1998 |
Kurihara N, Ishizuka S, Tatsumi J, Arai F, Ikeda K, Roodman GD. 23( S )25( R )-1,25-Dihydroxyvitamin D 3 -lactone, a naturally occurring metabolite of 1,25-dihydroxyvitamin D 3 , inhibits osteoclast-like cell formation in human bone marrow cultures Journal of Bone and Mineral Metabolism. 16: 5-10. DOI: 10.1007/s007740050021 |
0.306 |
|
| 1997 |
Roodman GD. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer. 80: 1557-63. PMID 9362422 DOI: 10.1002/(Sici)1097-0142(19971015)80:8+<1557::Aid-Cncr5>3.0.Co;2-H |
0.511 |
|
| 1997 |
Uy HL, Mundy GR, Boyce BF, Story BM, Dunstan CR, Yin JJ, Roodman GD, Guise TA. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Research. 57: 3194-9. PMID 9242449 |
0.398 |
|
| 1997 |
Reddy SV, Singer FR, Mallette L, Roodman GD. Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with Paget disease. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 11: 1602-7. PMID 8915767 DOI: 10.1002/Jbmr.5650111103 |
0.447 |
|
| 1997 |
Roodman GD. Paget's disease and osteoclast biology. Bone. 19: 209-12. PMID 8873960 DOI: 10.1016/8756-3282(96)00211-6 |
0.354 |
|
| 1997 |
Roodman GD. Advances in bone biology: the osteoclast. Endocrine Reviews. 17: 308-32. PMID 8854048 DOI: 10.1210/edrv-17-4-308 |
0.439 |
|
| 1997 |
Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 11: 150-9. PMID 8822338 DOI: 10.1002/JBMR.5650110203 |
0.341 |
|
| 1996 |
Alsina M, Guise TA, Roodman GD. Cytokine regulation of bone cell differentiation. Vitamins and Hormones. 52: 63-98. PMID 8909157 DOI: 10.1016/S0083-6729(08)60407-0 |
0.388 |
|
| 1996 |
Whyte MP, Leelawattana R, Reddy SV, Roodman GD. Absence of paramyxo virus transcripts in juvenile Paget bone disease. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 11: 1041. PMID 8797127 DOI: 10.1002/JBMR.5650110724 |
0.32 |
|
| 1996 |
Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 10: 1478-87. PMID 8686503 DOI: 10.1002/JBMR.5650101008 |
0.392 |
|
| 1996 |
Devlin RD, Bone HG, Roodman GD. Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. The Journal of Clinical Endocrinology and Metabolism. 81: 1893-7. PMID 8626854 DOI: 10.1210/jcem.81.5.8626854 |
0.366 |
|
| 1996 |
Alsina M, Boyce B, Devlin RD, Anderson JL, Craig F, Mundy GR, Roodman GD. Development of an in vivo model of human multiple myeloma bone disease. Blood. 87: 1495-501. PMID 8608240 |
0.433 |
|
| 1996 |
Roodman GD. Osteoclast function in Paget's disease and multiple myeloma. Bone. 17: 57S-61S. PMID 8579899 DOI: 10.1016/8756-3282(95)00179-H |
0.372 |
|
| 1996 |
Alsina M, Boyce BF, Mundy GR, Roodman GD. An in vivo model of human multiple myeloma bone disease. Stem Cells (Dayton, Ohio). 48-50. PMID 8520511 |
0.357 |
|
| 1996 |
Alsina M, Boyce B, Devlin R, Anderson J, Craig F, Mundy G, Roodman G. Development of an in vivo model of human multiple myeloma bone disease Blood. 87: 1495-1501. DOI: 10.1182/Blood.V87.4.1495.Bloodjournal8741495 |
0.433 |
|
| 1995 |
de la Mata J, Uy HL, Guise TA, Story B, Boyce BF, Mundy GR, Roodman GD. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. The Journal of Clinical Investigation. 95: 2846-52. PMID 7769125 DOI: 10.1172/JCI117990 |
0.356 |
|
| 1995 |
Uy HL, Dallas M, Calland JW, Boyce BF, Mundy GR, Roodman GD. Use of an in vivo model to determine the effects of interleukin-1 on cells at different stages in the osteoclast lineage. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 10: 295-301. PMID 7754810 DOI: 10.1002/JBMR.5650100217 |
0.392 |
|
| 1995 |
Uy HL, Guise TA, De La Mata J, Taylor SD, Story BM, Dallas MR, Boyce BF, Mundy GR, Roodman GD. Effects of parathyroid hormone (PTH)-related protein and PTH on osteoclasts and osteoclast precursors in vivo. Endocrinology. 136: 3207-12. PMID 7628353 DOI: 10.1210/endo.136.8.7628353 |
0.392 |
|
| 1995 |
Takahashi S, Reddy SV, Dallas M, Devlin R, Chou JY, Roodman GD. Development and characterization of a human marrow stromal cell line that enhances osteoclast-like cell formation. Endocrinology. 136: 1441-9. PMID 7534699 DOI: 10.1210/endo.136.4.7534699 |
0.374 |
|
| 1995 |
Roodman GD. Application of Bone Marrow Cultures to the Study of Osteoclast Formation and Osteoclast Precursors in Man Calcified Tissue International. 56: S22-S23. DOI: 10.1007/BF03354645 |
0.359 |
|
| 1994 |
Roodman GD. Role of cytokines in the regulation of bone resorption. Calcified Tissue International. S94-8. PMID 8275387 DOI: 10.1007/BF01673412 |
0.45 |
|
| 1994 |
Reddy SV, Scarcez T, Windle JJ, Leach RJ, Hundley JE, Chirgwin JM, Chou JY, Roodman GD. Cloning and characterization of the 5'-flanking region of the mouse tartrate-resistant acid phosphatase gene. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 8: 1263-70. PMID 8256664 DOI: 10.1002/Jbmr.5650081015 |
0.391 |
|
| 1994 |
Reddy SV, Takahashi S, Dallas M, Williams RE, Neckers L, Roodman GD. Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 9: 753-7. PMID 8053406 DOI: 10.1002/JBMR.5650090522 |
0.38 |
|
| 1994 |
Takahashi S, Reddy SV, Chirgwin JM, Devlin R, Haipek C, Anderson J, Roodman GD. Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption. The Journal of Biological Chemistry. 269: 28696-701. PMID 7961821 |
0.394 |
|
| 1994 |
Mills BG, Frausto A, Singer FR, Ohsaki Y, Demulder A, Roodman GD. Multinucleated cells formed in vitro from Paget's bone marrow express viral antigens. Bone. 15: 443-8. PMID 7917585 DOI: 10.1016/8756-3282(94)90823-0 |
0.322 |
|
| 1993 |
Gallwitz WE, Mundy GR, Lee CH, Qiao M, Roodman GD, Raftery M, Gaskell SJ, Bonewald LF. 5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices. The Journal of Biological Chemistry. 268: 10087-94. PMID 8486677 |
0.391 |
|
| 1993 |
Marshall MV, Marshall MH, Degen DR, Roodman GD, Kuhn JG, Ross ME, Von Hoff DD. In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units Stem Cells. 11: 62-69. PMID 8457783 DOI: 10.1002/Stem.5530110111 |
0.333 |
|
| 1993 |
Demulder A, Takahashi S, Singer FR, Hosking DJ, Roodman GD. Abnormalities in osteoclast precursors and marrow accessory cells in Paget's disease. Endocrinology. 133: 1978-82. PMID 7691583 DOI: 10.1210/endo.133.5.7691583 |
0.308 |
|
| 1993 |
Demulder A, Suggs SV, Zsebo KM, Scarcez T, Roodman GD. Effects of stem cell factor on osteoclast-like cell formation in long-term human marrow cultures. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 7: 1337-44. PMID 1281606 DOI: 10.1002/JBMR.5650071114 |
0.329 |
|
| 1992 |
Roodman GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, Smith JF, Singer FR. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. The Journal of Clinical Investigation. 89: 46-52. PMID 1729280 DOI: 10.1172/JCI115584 |
0.402 |
|
| 1992 |
Mundy GR, Roodman GD, Bonewald LF, Yoneda T, Sabatini M. Effects of TNF and lymphotoxin on bone cells. Immunology Series. 56: 483-98. PMID 1550873 |
0.416 |
|
| 1992 |
Ohsaki Y, Takahashi S, Scarcez T, Demulder A, Nishihara T, Williams R, Roodman GD. Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone. Endocrinology. 131: 2229-34. PMID 1425421 DOI: 10.1210/endo.131.5.1425421 |
0.366 |
|
| 1991 |
Kurihara N, Roodman GD. Interferons-alpha and -gamma inhibit interleukin-1 beta-stimulated osteoclast-like cell formation in long-term human marrow cultures. Journal of Interferon Research. 10: 541-7. PMID 2125633 DOI: 10.1089/jir.1990.10.541 |
0.318 |
|
| 1991 |
Roodman GD. Osteoclast differentiation. Critical Reviews in Oral Biology and Medicine : An Official Publication of the American Association of Oral Biologists. 2: 389-409. PMID 1892993 DOI: 10.1177/10454411910020030601 |
0.379 |
|
| 1991 |
Mundy GR, Roodman GD, Bonewald LF, Oreffo RO, Boyce BF. Assays for bone resorption and bone formation. Methods in Enzymology. 198: 502-10. PMID 1857238 DOI: 10.1016/0076-6879(91)98049-C |
0.372 |
|
| 1990 |
Chenu C, Kurihara N, Mundy GR, Roodman GD. Prostaglandin E2 inhibits formation of osteoclastlike cells in long-term human marrow cultures but is not a mediator of the inhibitory effects of transforming growth factor beta. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 5: 677-81. PMID 2396495 DOI: 10.1002/Jbmr.5650050703 |
0.401 |
|
| 1990 |
Kukita A, Bonewald L, Rosen D, Seyedin S, Mundy GR, Roodman GD. Osteoinductive factor inhibits formation of human osteoclast-like cells. Proceedings of the National Academy of Sciences of the United States of America. 87: 3023-6. PMID 2326263 DOI: 10.1073/pnas.87.8.3023 |
0.348 |
|
| 1990 |
Kukita A, Chenu C, McManus LM, Mundy GR, Roodman GD. Atypical multinucleated cells form in long-term marrow cultures from patients with Paget's disease. The Journal of Clinical Investigation. 85: 1280-6. PMID 2318982 DOI: 10.1172/JCI114565 |
0.34 |
|
| 1989 |
Pfeilschifter J, Chenu C, Bird A, Mundy GR, Roodman GD. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 4: 113-8. PMID 2785743 DOI: 10.1002/jbmr.5650040116 |
0.301 |
|
| 1989 |
Takahashi N, Kukita T, MacDonald BR, Bird A, Mundy GR, McManus LM, Miller M, Boyde A, Jones SJ, Roodman GD. Osteoclast-like cells form in long-term human bone marrow but not in peripheral blood cultures. The Journal of Clinical Investigation. 83: 543-50. PMID 2783589 DOI: 10.1172/Jci113916 |
0.352 |
|
| 1989 |
Kukita T, Roodman GD. Development of a monoclonal antibody to osteoclasts formed in vitro which recognizes mononuclear osteoclast precursors in the marrow. Endocrinology. 125: 630-7. PMID 2752970 DOI: 10.1210/Endo-125-2-630 |
0.395 |
|
| 1989 |
Johnson RA, Roodman GD. Hematologic manifestations of malignancy. Disease-a-Month : Dm. 35: 721-68. PMID 2680358 DOI: 10.1016/0011-5029(89)90011-4 |
0.308 |
|
| 1989 |
Kukita T, McManus LM, Miller M, Civin C, Roodman GD. Osteoclast-like cells formed in long-term human bone marrow cultures express a similar surface phenotype as authentic osteoclasts. Laboratory Investigation; a Journal of Technical Methods and Pathology. 60: 532-8. PMID 2468824 |
0.343 |
|
| 1988 |
MacDonald BR, Mundy GR, Clark S, Wang EA, Kuehl TJ, Stanley ER, Roodman GD. Effects of human recombinant CSF-GM and highly purified CSF-1 on the formation of multinucleated cells with osteoclast characteristics in long-term bone marrow cultures. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 1: 227-33. PMID 3332553 DOI: 10.1002/JBMR.5650010210 |
0.377 |
|
| 1987 |
MacDonald BR, Takahashi N, McManus LM, Holahan J, Mundy GR, Roodman GD. Formation of multinucleated cells that respond to osteotropic hormones in long term human bone marrow cultures. Endocrinology. 120: 2326-33. PMID 3569133 DOI: 10.1210/endo-120-6-2326 |
0.399 |
|
| 1984 |
Ibbotson KJ, Roodman GD, McManus LM, Mundy GR. Identification and characterization of osteoclast-like cells and their progenitors in cultures of feline marrow mononuclear cells. The Journal of Cell Biology. 99: 471-80. PMID 6589224 DOI: 10.1083/jcb.99.2.471 |
0.355 |
|
| 1980 |
Roodman GD, Ascensao JL, Banisadre M, Bloom PM, Zanjani ED. Autoimmune pancytopenia. Lymphocyte inhibition of autologous but not allogenic bone marrow growth in vitro American Journal of Medicine. 69: 325-328. PMID 7405950 DOI: 10.1016/0002-9343(80)90393-9 |
0.316 |
|
| Show low-probability matches. |